Matches in Wikidata for { <http://www.wikidata.org/entity/Q86169197> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- Q86169197 description "clinical trial" @default.
- Q86169197 description "ensayu clínicu" @default.
- Q86169197 description "klinisch onderzoek" @default.
- Q86169197 description "клінічне випробування" @default.
- Q86169197 name "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (2012-10-31)" @default.
- Q86169197 name "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (2012-10-31)" @default.
- Q86169197 type Item @default.
- Q86169197 label "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (2012-10-31)" @default.
- Q86169197 label "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (2012-10-31)" @default.
- Q86169197 prefLabel "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (2012-10-31)" @default.
- Q86169197 prefLabel "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) (2012-10-31)" @default.
- Q86169197 P1050 Q86169197-4EFD42AF-E958-4B02-9C8D-7BD353F7D3F6 @default.
- Q86169197 P1132 Q86169197-B5ABD483-0E18-4698-9670-91D3189B06A6 @default.
- Q86169197 P1476 Q86169197-E38CA621-0FCD-4DAE-925B-4C4CE8F9E60A @default.
- Q86169197 P17 Q86169197-0EFEB8C5-60C4-49C7-B497-C6B6EB7E86D6 @default.
- Q86169197 P17 Q86169197-17AE3D28-A97C-4E96-9B31-4DFEA56DD460 @default.
- Q86169197 P17 Q86169197-1D9CBA7B-0FEB-4887-8EDF-DEF6F19952F4 @default.
- Q86169197 P17 Q86169197-211B3E3E-8F08-40E1-B01B-DA86631E7F7F @default.
- Q86169197 P17 Q86169197-34A60AAF-732B-4FE5-8451-1897CF1302C8 @default.
- Q86169197 P17 Q86169197-36275CE7-3FE3-40D7-9D02-52D89ACA031E @default.
- Q86169197 P17 Q86169197-50CC1B4A-D7D4-4006-8A98-1439FAF4ACE7 @default.
- Q86169197 P17 Q86169197-637F7AFC-5AB8-48AE-A6A2-FFE124EA85CF @default.
- Q86169197 P17 Q86169197-8660C296-2CE7-4BE6-BE3B-A636195987EC @default.
- Q86169197 P17 Q86169197-8F1E7720-CB8E-49EF-A830-68EE5854CA2C @default.
- Q86169197 P17 Q86169197-92445327-C79B-4343-A03B-5EA3B6268F09 @default.
- Q86169197 P17 Q86169197-98D450B8-E84C-4656-8E80-D3ED12318730 @default.
- Q86169197 P17 Q86169197-B13E19FD-B912-4178-9A76-C54FCC697ADC @default.
- Q86169197 P17 Q86169197-E20EC4F7-1706-4189-8189-7428B3FF2718 @default.
- Q86169197 P2899 Q86169197-FFD26990-8ECC-487A-875D-0F6E0386AAC4 @default.
- Q86169197 P3098 Q86169197-025EAE9D-06CD-4111-9E0F-D4EF2AAF54DC @default.
- Q86169197 P31 Q86169197-02AE3015-FA42-492C-986A-BD32EC20226B @default.
- Q86169197 P4135 Q86169197-DF445E01-BE4A-4925-995F-855BAB1A5C45 @default.
- Q86169197 P4844 Q86169197-85AAD2EC-51CF-47F9-84C2-ECB4E496ED3F @default.
- Q86169197 P4844 Q86169197-94656A98-9DDB-49E1-A123-F038FC07A46B @default.
- Q86169197 P4844 Q86169197-97A61691-6CAF-4207-A6B6-38C59B799123 @default.
- Q86169197 P4844 Q86169197-AE67A5C4-58D9-4046-909B-EEB4B0A25198 @default.
- Q86169197 P4844 Q86169197-DFF4EC91-F7E0-48F7-B064-7B8ECDC3BDD2 @default.
- Q86169197 P4844 Q86169197-E46F6D27-4F91-45E7-A9EE-36BB557CEB52 @default.
- Q86169197 P580 Q86169197-1619AD66-2A57-4B13-BC46-6D7CE0586AE3 @default.
- Q86169197 P582 Q86169197-FDDE6D11-9D6A-443F-B41A-117FD4E0B208 @default.
- Q86169197 P6099 Q86169197-D053EDF8-1074-4E64-8010-7465AB9C3AAF @default.
- Q86169197 P8363 Q86169197-D7978866-292A-4DCD-BC74-66453C451025 @default.
- Q86169197 P859 Q86169197-1B14F562-C545-40A5-BF59-0653D3227376 @default.
- Q86169197 P1050 Q506652 @default.
- Q86169197 P1132 "+641" @default.
- Q86169197 P1476 "A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults" @default.
- Q86169197 P17 Q183 @default.
- Q86169197 P17 Q212 @default.
- Q86169197 P17 Q218 @default.
- Q86169197 P17 Q219 @default.
- Q86169197 P17 Q224 @default.
- Q86169197 P17 Q29 @default.
- Q86169197 P17 Q30 @default.
- Q86169197 P17 Q36 @default.
- Q86169197 P17 Q38 @default.
- Q86169197 P17 Q414 @default.
- Q86169197 P17 Q419 @default.
- Q86169197 P17 Q801 @default.
- Q86169197 P17 Q865 @default.
- Q86169197 P17 Q96 @default.
- Q86169197 P2899 "+18" @default.
- Q86169197 P3098 "NCT01599806" @default.
- Q86169197 P31 Q30612 @default.
- Q86169197 P4135 "+90" @default.
- Q86169197 P4844 Q15410251 @default.
- Q86169197 P4844 Q256602 @default.
- Q86169197 P4844 Q411552 @default.
- Q86169197 P4844 Q415843 @default.
- Q86169197 P4844 Q422665 @default.
- Q86169197 P4844 Q808845 @default.
- Q86169197 P580 "2012-10-01T00:00:00Z" @default.
- Q86169197 P582 "2014-08-01T00:00:00Z" @default.
- Q86169197 P6099 Q42824827 @default.
- Q86169197 P8363 Q78089383 @default.
- Q86169197 P859 Q206921 @default.